ARTICLE | Clinical News
Onglyza saxagliptin: Phase III data
September 15, 2008 7:00 AM UTC
A 24-week, double-blind, international Phase III trial in 565 patients with Type II diabetes receiving thiazolidinedione (TZD) showed that Onglyza saxagliptin met the primary endpoint. Patients receiv...